<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03918265</url>
  </required_header>
  <id_info>
    <org_study_id>tacrolimus-2</org_study_id>
    <nct_id>NCT03918265</nct_id>
  </id_info>
  <brief_title>Tacrolimus Treatment for Refractory Autoimmune Cytopenia</brief_title>
  <official_title>Tacrolimus Treatment for Refractory Autoimmune Cytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA), pure red cell aplasia
      (PRCA), Evans syndrome (ES), usually has good responses to steroids therapies as first line,
      but there is a considerable percentage of patients who relapse, become refractory or
      dependent on steroids to maintain an acceptable level of hemoglobin or platelets. The effects
      of the second line therapy are also not satisfactory and sometimes not available. The
      investigators aim to explore the efficacy and side-effect of tacrolimus for refractory
      autoimmune cytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tacrolimus binds FKBP12 with high affinity after entry into cytoplasm, suppresses calcineurin
      activity and prevents nuclear translocation of transcription factors such as NF-AT that are
      involved in IL-2 gene transcription. As a result, T-cell activation is inhibited with a
      subsequent reduction in the production of cytokines that include IL-2, TNF-α, IL-3, IL-4,
      IFN-γ, IL-6 and IL-10; B-cell activation, class-switching and immunoglobulin production are
      also attenuated. Reports on the use of tarcrolimus in the treatment of autoimmune cytopenia
      are anecdotal and describe therapy with a variety of drug dosages.

      The purpose of this study is to evaluate the effect of tacrolimus on patients with refractory
      autoimmune cytopenia, the side-effects will be documented and plasma concentration of
      tacrolimus will be monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2019</start_date>
  <completion_date type="Anticipated">November 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>6 months</time_frame>
    <description>Hemoglobin level in g/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>6 months</time_frame>
    <description>Platelet count in /L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>2 years</time_frame>
    <description>Hemoglobin level in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>2 years</time_frame>
    <description>Platelet count in /L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Pure Red Cell Aplasia</condition>
  <condition>Evans Syndrome</condition>
  <arm_group>
    <arm_group_label>Efficiency of tacrolimus on autoimmune cytopenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A prospective research of the tacrolimus efficiency on refractory autoimmune cytopenia patients. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.
Medication time should last at least 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study</description>
    <arm_group_label>Efficiency of tacrolimus on autoimmune cytopenia</arm_group_label>
    <other_name>tacrolimus capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Refractory autoimmune cytopenia, including autoimmune hemolytic anemia, pure red cell
             aplasia, Evans syndrome.

          -  18-80 years old.

          -  No response or intolerant to first and second line therapies.

          -  ECOG Performance Status of 0-2

          -  Written informed consent.

        Exclusion Criteria:

          -  Other diseases which might cause hematological abnormalities.

          -  Response and well tolerate to first or second line therapy.

          -  Patients who are under 18-year-old or over 80-year-old.

          -  Pregnant or lactating.

          -  Patients unwilling to or unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bing Hang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruoxi Zhang, M.D.</last_name>
    <phone>+86 18510064839</phone>
    <email>rx_zh15@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruoxi Zhang, MD</last_name>
      <phone>+86 18510064839</phone>
      <email>rx_zh15@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Li Y, Feng X. Efficacy and safety of tacrolimus in systemic lupus erythematosus patients with refractory thrombocytopenia: a retrospective study. Lupus. 2018 Jan;27(1):60-65. doi: 10.1177/0961203317711011. Epub 2017 May 31.</citation>
    <PMID>28566017</PMID>
  </reference>
  <reference>
    <citation>Tabchi S, Hanna C, Kourie HR, Aftimos P, El Osta L, Ghosn M. Successful treatment of Evans syndrome with Tacrolimus. Invest New Drugs. 2015 Feb;33(1):254-6. doi: 10.1007/s10637-014-0155-9. Epub 2014 Sep 12.</citation>
    <PMID>25209619</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>December 1, 2019</last_update_submitted>
  <last_update_submitted_qc>December 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Refractory autoimmune cytopenia</keyword>
  <keyword>Prospective study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Red-Cell Aplasia, Pure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

